Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

Panelists discuss how combination trials like VIALE-A and VIALE-C have demonstrated venetoclax’s survival benefits when added to hypomethylating agents, opening doors for numerous combination studies ...

Kura Oncology holds a strong cash position with Komzifti FDA approval and frontline AML expansion potential. Read why KURA ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...

A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...

A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.

Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how ...

Acute myeloid leukemia (AML) is a rare and aggressive hematologic malignancy. AML progresses rapidly and is indicated by an excess of immature white blood cells. It is caused by high mutational burden ...